Cryoablation Shows 99% Recurrence-Free Rate for Breast Cancer in Top Journal, IceCure Preps Japan Submission
ICCM has more than doubled off its 52-week low of $2.12 on elevated volume (5.7× avg).
Summary
IceCure highlighted a new peer-reviewed article in the International Journal of Surgery, demonstrating its ProSense® cryoablation technology's advantages over radiofrequency ablation for early-stage breast cancer. The article cited a 99.02% recurrence-free rate from over 600 patients with up to 17 years of follow-up. This strong clinical validation from a top-tier journal significantly bolsters the credibility and market potential of ProSense® for a major indication. This follows recent positive Q1 revenue growth for ProSense® and a successful $5.5 million private placement. IceCure is preparing for a regulatory submission for breast cancer in Japan by its distributor, Terumo Corporation, in the second half of 2026.
At the time of this announcement, ICCM was trading at $6.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.6M. The 52-week trading range was $2.12 to $42.00. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: PR Newswire.